Shahrokh F. Shariat, M.D.
Urology
Honors and Awards
(selected from 62)
1999-Grant, Methods in Clinical Cancer Research. Vail, Colorado; The American Association for Cancer Research and the American Society of Clinical Oncology
2000-Travel Grant, Molecular Biology in Clinical Oncology. Aspen, Colorado; The American Association for Cancer Research
2001-Glaxo SmithKline Scholar Award, for promising clinical/translational cancer research; American Association of Cancer Research
2001-Pfizer Scholar in Urology Award
2001-Winner of the Science Day 2001 Project – Baylor College of Medicine, Houston, TX
2001-First Place Poster, 2nd Alexander Research Symposium, Baylor College of Medicine, Houston, TX, Expression of TGF-β1 and its receptors in transitional cell carcinoma of the bladder.
2002-AUA / Praecis Gerald P. Murphy Scholar
2002-American Cancer Society Institutional Research Grant (IRG#93-034-06), Development of a nomogram for prediction of the development of distant prostate cancer metastases and mortality.
2002-Best Poster, Society of Urologic Oncology Annual Meeting, National Cancer Institute,December 13 - 14, 2002, National Institutes of Health, Bethesda, Maryland. Preoperative serum levels of pro-PSA isoforms are associated with biologicallyaggressive prostate cancer.
2003-Two thousand Outstanding Intellectuals of the 21st Century, International Biographical Center, Cambridge, England (Registration number 965274)
2004-Best Poster, Society for Urodynamics and Female Urology 2004 Meeting. Scottsdale, Arizona.February 26-29, 2004.
2004-"Best Poster" in urothelial cancer, European Association of Urology Annual Meeting, Vienna, March 26, 2004.Urine detection of survivin is a sensitive marker for the non-invasive diagnosis of bladder cancer.
2005-"Best Poster" in urogenital trauma, 21st European Association of Urology Annual Meeting, Paris, April 5-8, 2006. Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale.
2006-"Best Poster" in bladder cancer: diagnosis and staging III, 21st European Association of Urology Annual Meeting, Paris, April 5-8, 2006. Survivin expression is associated with bladder cancer presence, stage, progression, metastasis, and mortality.
2006-AUA / Threshold Pharmaceuticals Gerald P. Murphy Scholar
2007-AUA / Novacea Gerald P. Murphy Scholar
2007-Listed in the "Guide to America's Top Urologists 2007" – Consumers' Research Council of America is an independent research company based in Washington, DC that evaluated professional services throughout America (www.consumerresearchcncl.org).
2007-"Best Poster" in prostate cancer: staging I, 22nd European Association of Urology Annual Meeting, Berlin, March 21-4, 2007. Caveolin-1 overexpression is associateat with aggressive prostate cancer recurrence.
2007- Best Poster, Society of Urologic Oncology Eight Annual Meeting, National Cancer Institute, November 29th-December 1st, 2007, National Institutes of Health, Bethesda, Maryland. Multiple bio-markers for the prediction of bladder cancer recurrence and mortality.
2008-"Best Poster" in prostate cancer: prognostic factors and predictors of outcome, 23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-9, 2008. Early post-operative plasma transforming growth factor-β1 is a powerful predictor of biochemical progression after radical prostatectomy.
2008-"Best Poster" in diagnosis and staging of urothelial tumours II, 23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-9, 2008. Multiple bio-markers for the prediction of bladder cancer recurrence and mortality.
2008-"Best Poster" in Prostate Cancer: Staging (I), American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008. Improved prediction of disease relapse after radical prostatectomy using a panel of preoperative blood-based biomarkers.
2008-"Best Poster" in Prostate Cancer: Advanced (I), American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008. J.Urol 179(4): 186, 2008. The effect of androgen deprivation therapy on the rate of subsequent non-cancer morbidities.
2008-"Best Poster" in Urothelial Cancer: Surgical Therapy, American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008. More extensive lymphadenectomy improves the prognosis of patients with upper tract urothelial carcinoma without nodal metastases.
2008-Reviewer of the month January – European Urology
2008-ASCO Cancer Foundation Merit Award, American Society of Clinical Oncology Cancer Foundation and the ASCO/National Cancer Institute/EORTC Scientific Committee, Annual Meeting on Molecular Markers in Cancer, Hollywood, FL.
2008-Listed in the "Guide to America's Top Urologists 2008"
2008-Best Poster, Society of Urologic Oncology Annual Meeting, National Cancer Institute, December 4-6th, 2008, National Institutes of Health, Bethesda, MD. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with bladder cancer.
2009-Merit Award, ASCO Cancer Foundation Board of Directors and the 2009 Genitourinary Cancers SymposiumProgram Committee, Genitourinary Cancers Symposium in Orlando, FL. Use of pre-treatment biomarker levels to improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence
2009-"Best Poster" in Transitional Cell Carcinoma Pathology, 24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009. Predictive value of the combination of immunohistochemical markers in patients with pT1 disease at radical cystectomy.
2009-"Best Poster" in Management of Advanced Urothelial Pathology, 24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009. Improved prediction of clinical outcomes in patients with advanced bladder cancer using a panel of four cell cycle regulators.
2009-"Best Poster" in Upper and Lower Urinary Tract Carcinoma, 24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009. Proposal for subclassification of pT3 urothelial cancer of the renal pelvis.
2009-First Prize for the Best Abstract, 25th European Association of Urology Annual Meeting, Barcelona, Spain. April 16-20, 2010. Her2 expression status provides independent prognostic information in patients with urothelial carcinoma of the bladder: a rationale for targeted therapy.
2010-"Best Poster" in Urothelial Cancer: Natural history and pathophysiology/markers, American Urological Association Annual Meeting, San Francisco, CA, May 29-June 3, 2010. J.Urol 183(4): 662-663, 2010.
2011-BJU Int Reviewer of Year 2011,
2011-"Best Poster" in Hematuria and bladder cancer diagnosis session, 26th Annual EAU Congress. 18-22 March 2011, Vienna, Austria. Risk assessment of patients who present with asymptomatic hematuria: Development and validation of a nomogram for prediction of bladder cancer presence. 3/19/2011 Abstract 149, page 128.
2011-"Best Poster", 26th Annual EAU Congress. 18-22 March 2011, Vienna, Austria. pT3 substaging is a prognostic indicator in lymph node negative urothelial carcinoma of the bladder, 3/19/2011
